Open Medicine (Sep 2017)

Therapeutic nanomedicine surmounts the limitations of pharmacotherapy

  • Odiba Arome,
  • Ottah Victoria,
  • Ottah Comfort,
  • Anunobi Ogechukwu,
  • Ukegbu Chimere,
  • Edeke Affiong,
  • Uroko Robert,
  • Omeje Kingsley

DOI
https://doi.org/10.1515/med-2017-0041
Journal volume & issue
Vol. 12, no. 1
pp. 271 – 287

Abstract

Read online

Science always strives to find an improved way of doing things and nanoscience is one such approach. Nanomaterials are suitable for pharmaceutical applications mostly because of their size which facilitates absorption, distribution, metabolism and excretion of the nanoparticles. Whether labile or insoluble nanoparticles, their cytotoxic effect on malignant cells has moved the use of nanomedicine into focus. Since nanomedicine can be described as the science and technology of diagnosing, treating and preventing diseases towards ultimately improving human health, a lot of nanotechnology options have received approval by various regulatory agencies. Nanodrugs also have been discovered to be more precise in targeting the desired site, hence maximizing the therapeutic effects, while minimizing side-effects on the rest of the body. This unique property and more has made nanomedicine popular in therapeutic medicine employing nanotechnology in genetic therapy, drug encapsulation, enzyme manipulation and control, tissue engineering, target drug delivery, pharmacogenomics, stem cell and cloning, and even virus-based hybrids. This review highlights nanoproducts that are in development and have gained approval through one clinical trial stage or the other.

Keywords